IGF2BP1 and cancer: Additionally, the research by Yang Liu et al. introduced cucurbitacin B (CuB) as a novel inhibitor targeting IGF2BP1, enhancing the immune response and reducing cancer progression in hepatocellular carcinoma by affecting m6A-modified transcripts [70].